Sign Out
Pharmacotherapeutic group: Electrolyte solution, ATC code: B05XA14.
Pharmacology: Pharmacodynamics: Glycophos is a concentrated additive solution of phosphate and sodium.
Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.
Pharmacokinetics: To become available, it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/L. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
No pharmacokinetic data is available for neonates. However, hyperphosphatemia is unlikely at the recommended dosage.
